{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:20Z","timestamp":1790790200095,"version":"4.1.0"},"reference-count":23,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Describe the clinical and economic burden of hospitalizations for amyloid light chain (AL) amyloidosis.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            This retrospective analysis used nationally representative hospital discharge data (2017\u20132020) to report discharge status, resource use\u00a0and costs for hospitalizations among patients with AL amyloidosis.\n            <jats:bold>Results:<\/jats:bold>\n            Of 1341 patients identified, 92% were discharged alive and 8% experienced in-hospital death. Compared with the average US hospital stay during 2017\u20132019 (4.7\u00a0days, mean costs of $13,046\u00a0and mean charges of $54,496), hospital stays for AL amyloidosis were longer and costlier (9.7\u00a0days, $27,098.61, $111,233.91), especially in patients with in-hospital death (12.2\u00a0days, $44,966, $182,338.18).\n            <jats:bold>Conclusion:<\/jats:bold>\n            AL amyloidosis is associated with significant clinical and economic burden.\n          <\/jats:p>","DOI":"10.2217\/cer-2022-0185","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T07:30:56Z","timestamp":1670484656000},"source":"Crossref","is-referenced-by-count":3,"title":["In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database"],"prefix":"10.57264","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-4285","authenticated-orcid":false,"given":"Tiffany P","family":"Quock","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research, Prothena Biosciences Inc, South San Francisco, CA\u00a094080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-5643","authenticated-orcid":false,"given":"Anita","family":"D'Souza","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, WI\u00a053226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-5536","authenticated-orcid":false,"given":"Michael S","family":"Broder","sequence":"additional","affiliation":[{"name":"Real World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA\u00a090212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-8569","authenticated-orcid":false,"given":"Katalin","family":"Bognar","sequence":"additional","affiliation":[{"name":"Real World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA\u00a090212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-6153","authenticated-orcid":false,"given":"Eunice","family":"Chang","sequence":"additional","affiliation":[{"name":"Real World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA\u00a090212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0818-5113","authenticated-orcid":false,"given":"Marian H","family":"Tarbox","sequence":"additional","affiliation":[{"name":"Real World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA\u00a090212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"5","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive review of AL amyloidosis: some practical recommendations","volume":"11","author":"Al Hamed R","year":"2021","unstructured":"Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau J-L, Mohty M. Comprehensive review of AL amyloidosis: some practical recommendations. Blood Cancer J. 11(5), 97 (2021).","journal-title":"Blood Cancer J."},{"issue":"5","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-021-00483-7","article-title":"Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021","volume":"11","author":"Hasib Sidiqi M","year":"2021","unstructured":"Hasib Sidiqi M, Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J. 11(5), 90 (2021).","journal-title":"Blood Cancer J."},{"issue":"4","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000508287","article-title":"Prognosis and staging of AL amyloidosis","volume":"143","author":"Dittrich T","year":"2020","unstructured":"Dittrich T, Kimmich C, Hegenbart U, Sch\u00f6nland SO. Prognosis and staging of AL amyloidosis. Acta Haematol. 143(4), 388\u2013400 (2020).","journal-title":"Acta Haematol."},{"issue":"1","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1038\/s41598-019-44912-x","article-title":"Predictors of mortality in light chain cardiac amyloidosis with heart failure","volume":"9","author":"Tahir UA","year":"2019","unstructured":"Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of mortality in light chain cardiac amyloidosis with heart failure. Sci. Rep. 9(1), 8552 (2019).","journal-title":"Sci. Rep."},{"issue":"7","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"95","author":"Gertz MA","year":"2020","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am. J. Hematol. 95(7), 848\u2013860 (2020).","journal-title":"Am. J. Hematol."},{"issue":"4","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.14740\/jh866","article-title":"Curent updates on the management of AL amyloidosis","volume":"10","author":"Elsayed M","year":"2021","unstructured":"Elsayed M, Usher S, Habib MH Curent updates on the management of AL amyloidosis. J. Hematol. 10(4), 147\u2013161 (2021).","journal-title":"J. Hematol."},{"issue":"2","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland KL","year":"2018","unstructured":"McCausland KL, White MK, Guthrie SD Light chain (AL) amyloidosis: the journey to diagnosis. Patient 11(2), 207\u2013216 (2018).","journal-title":"Patient"},{"issue":"14","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan M","year":"2017","unstructured":"Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart 103(14), 1065\u20131072 (2017).","journal-title":"Heart"},{"issue":"4","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s11136-021-02943-w","article-title":"Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study","volume":"31","author":"D'Souza A","year":"2022","unstructured":"D'Souza A, Myers J, Cusatis R Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study. Qual. Life Res. 31(4), 1083\u20131092 (2022).","journal-title":"Qual. Life Res."},{"issue":"11","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","article-title":"A changing landscape of mortality for systemic light chain amyloidosis","volume":"7","author":"Barrett CD","year":"2019","unstructured":"Barrett CD, Dobos K, Liedtke M A changing landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail. 7(11), 958\u2013966 (2019).","journal-title":"JACC Heart Fail."},{"key":"e_1_3_4_13_2","unstructured":"Kumar S Callender N Adekola K Anderson L Baljevic M Campagnaro E. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae ): Systemic Light Chain Amyloidosis Version 2. National Comprehensive Cancer Network. 2021 (2021). https:\/\/www.nccn.org\/guidelines\/category_1"},{"issue":"8","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron A","year":"2021","unstructured":"Staron A, Zheng L, Doros G Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 11(8), 139 (2021).","journal-title":"Blood Cancer J."},{"issue":"6","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/03007995.2017.1297930","article-title":"Disease burden of systemic light-chain amyloidosis: a systematic literature review","volume":"33","author":"Lin HM","year":"2017","unstructured":"Lin HM, Gao X, Cooke CE Disease burden of systemic light-chain amyloidosis: a systematic literature review. Curr. Med. Res. Opin. 33(6), 1017\u20131031 (2017).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/CEOR.S207127","article-title":"Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States","volume":"11","author":"Quock TP","year":"2019","unstructured":"Quock TP, Yan T, Tieu R, D'Souza A, Broder MS. Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States. Clin. Outcomes Res. 11, 431\u2013439 (2019).","journal-title":"Clin. Outcomes Res."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0100"},{"issue":"1","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2017.1411796","article-title":"Treatment patterns and health care resource utilization among patients with relapsed\/refractory systemic light chain amyloidosis","volume":"25","author":"Hari P","year":"2018","unstructured":"Hari P, Lin HM, Asche CV Treatment patterns and health care resource utilization among patients with relapsed\/refractory systemic light chain amyloidosis. Amyloid 25(1), 1\u20137 (2018).","journal-title":"Amyloid"},{"key":"e_1_3_4_19_2","unstructured":"Premier Applied Sciences \u00ae . Premier Healthcare Database White Paper: data that informs and performs [internet]. Premier Inc. (2020). https:\/\/learn.premierinc.com\/white-papers\/premier-healthcare- database-whitepaper"},{"key":"e_1_3_4_20_2","article-title":"Division of Consumer Prices and Price Indexes","author":"U.S. Bureau of Labor Statistics","year":"2021","unstructured":"U.S. Bureau of Labor Statistics. Division of Consumer Prices and Price Indexes. \u201cConsumer Price Index\u201d (2021). https:\/\/www.bls.gov\/cpi\/","journal-title":"\u201cConsumer Price Index\u201d"},{"issue":"9","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.24433","article-title":"Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment","volume":"91","author":"Gertz MA","year":"2016","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am. J. Hematol. 91(9), 947\u2013956 (2016).","journal-title":"Am. J. Hematol."},{"issue":"11","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.amjcard.2019.08.045","article-title":"Increasing rate of hospital admissions in patients with amyloidosis (from the National Inpatient Sample)","volume":"124","author":"Sperry BW","year":"2019","unstructured":"Sperry BW, Saeed IM, Raza S, Kennedy KF, Hanna M, Spertus JA. Increasing rate of hospital admissions in patients with amyloidosis (from the National Inpatient Sample). Am. J. Cardiol. 124(11), 1765\u20131769 (2019).","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/ejh.13679","article-title":"Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019","volume":"107","author":"Hester LL","year":"2021","unstructured":"Hester LL, Gifkins DM, Bellew K Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. Eur. J. Haematol. 107(4), 428\u2013435 (2021).","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) cardiac amyloidosis","volume":"68","author":"Falk RH","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) cardiac amyloidosis. J. Am. Coll. Cardiol. 68(12), 1323\u20131341 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar S","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J. Clin. Oncol. 30(9), 989\u2013995 (2012).","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.futuremedicine.com\/doi\/pdf\/10.2217\/cer-2022-0185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T14:57:45Z","timestamp":1676645865000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.2217\/cer-2022-0185"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0185","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"article-number":"e220185"}}